Eli Lilly Starts Phase 3 Trial for Selpercatinib

Date : 12/11/2019 @ 12:27PM
Source : Dow Jones News
Stock : Eli Lilly and Co (LLY)
Quote : 139.58  -1.85 (-1.31%) @ 9:07PM
After Hours
Last Trade
Last $ 139.58 ◊ 0.00 (0.00%)

Eli Lilly Starts Phase 3 Trial for Selpercatinib

Eli Lilly (NYSE:LLY)
Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more Eli Lilly Charts.
   By Dave Sebastian 

Eli Lilly and Co. (LLY) said it has started its first Phase 3 trial for selpercatinib on non-small cell lung cancer patients who haven't undergone treatment for metastatic disease.

The company said the trial aims to enroll 400 patients, who will receive either selpercatinib, also known as Loxo-292, or platinum-based and pemetrexed therapy with or without pembrolizumab as initial treatment.

Selpercatinib is an oral drug that aims to treat cancers with abnormalities in the rearranged during transfection kinase, Lilly said.

Write to Dave Sebastian at dave.sebastian@wsj.com


(END) Dow Jones Newswires

December 11, 2019 07:12 ET (12:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest LLY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.